All anti-CD20 monoclonal antibodies have similar efficacy and risks: No.

Treatment with the B cell-depleting anti-CD20 monoclonal antibodies (mAb) ocrelizumab, ofatumumab, rituximab and ublituximab results in profound reductions in magnetic resonance imaging disease activity in multiple sclerosis (MS). Data on clinical and magnetic resonance imaging (MRI) efficacy from Phase 3 studies are in the same range for ocrelizumab and ofatumumab and data from Phase 2 studies also indicate similar effect and safety for rituximab and ublituximab.1,2 Although all four mAbs are highly efficacious in depleting circulating B cells and in reducing disease activity, they may differ in their safety profile and in their ability to prevent worsening of disability and disease progression.